Anti-thymocyte globulin for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests an immune-suppressing medicine (anti-thymocyte globulin) in people with type 1 diabetes to see if it can help save the body's ability to make insulin. It is for people aged 5–40 who were diagnosed recently or have had diabetes for up to 2 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 5 to 40 years old.
- Your type 1 diabetes was diagnosed within the last 2 years.
- You still make some insulin (C-peptide level above 0.2 nmol/L).
- You test positive for at least one type 1 diabetes-related autoantibody (GAD65, IA-2, ZnT8, or insulin).
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
- You have not taken certain immune-modifying drugs or participated in other drug trials recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug golimumab (an immune-modulating medicine) can delay or prevent type 1 diabetes in people who have early signs of autoimmunity but still have normal blood sugar. It compares golimumab to a placebo (a dummy treatment) to see if it can protect the insulin-making cells in the pancreas.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
This study tests a new treatment called GNTI-122 for adults recently diagnosed with type 1 diabetes who still make some insulin. It aims to see if the treatment can help protect the cells that produce insulin.
This trial tests an oral medication that may help your body respond better to insulin. It's for people with type 1 diabetes who use an automated insulin pump and are willing to take a daily pill for 12 weeks.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.